Literature DB >> 31679420

Central EP3 (E Prostanoid 3) Receptors Mediate Salt-Sensitive Hypertension and Immune Activation.

Liang Xiao1, Hana A Itani2, Luciana Simao do Carmo1, Lucas S Carver1, Richard M Breyer3, David G Harrison1.   

Abstract

We recently identified a pathway underlying immune activation in hypertension. Proteins oxidatively modified by reactive isoLG (isolevuglandin) accumulate in dendritic cells (DCs). PGE2 (Prostaglandin E2) has been implicated in the inflammation associated with hypertension. We hypothesized that PGE2 via its EP (E prostanoid) 3 receptor contributes to DC activation in hypertension. EP3-/- mice and wild-type littermates were exposed to sequential hypertensive stimuli involving an initial 2-week exposure to the nitric oxide synthase inhibitor Nω-nitro-L-arginine methyl ester hydrochloride in drinking water, followed by a 2-week washout period, and a subsequent 4% high-salt diet for 3 weeks. In wild-type mice, this protocol increased systolic pressure from 123±2 to 148±8 mm Hg (P<0.05). This was associated with marked renal inflammation and a striking accumulation of isoLG adducts in splenic DCs. However, the increases in blood pressure, renal T-cell infiltration, and DC isoLG formation were completely prevented in EP3-/- mice. Similar protective effects were also observed in wild-type mice that received intracerebroventricular injection of a lentiviral vector encoding shRNA targeting the EP3 receptor. Further, in vitro experiments indicated that PGE2 also acts directly on DCs via its EP1 receptors to stimulate intracellular isoLG formation. Together, these findings provide new insight into how EP receptors in both the central nervous system and peripherally on DCs promote inflammation in salt-induced hypertension.

Entities:  

Keywords:  autonomic nervous system; blood pressure; dendritic cells; inflammation; reactive oxygen species

Mesh:

Substances:

Year:  2019        PMID: 31679420      PMCID: PMC7040566          DOI: 10.1161/HYPERTENSIONAHA.119.13850

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   9.897


  33 in total

1.  Angiotensin II-dependent hypertension requires cyclooxygenase 1-derived prostaglandin E2 and EP1 receptor signaling in the subfornical organ of the brain.

Authors:  Xian Cao; Jeffrey R Peterson; Gang Wang; Josef Anrather; Colin N Young; Mallikarjuna R Guruju; Melissa A Burmeister; Costantino Iadecola; Robin L Davisson
Journal:  Hypertension       Date:  2012-02-27       Impact factor: 10.190

2.  The PGE2 EP3 Receptor Regulates Diet-Induced Adiposity in Male Mice.

Authors:  Ryan P Ceddia; DaeKee Lee; Matthew F Maulis; Bethany A Carboneau; David W Threadgill; Greg Poffenberger; Ginger Milne; Kelli L Boyd; Alvin C Powers; Owen P McGuinness; Maureen Gannon; Richard M Breyer
Journal:  Endocrinology       Date:  2015-10-20       Impact factor: 4.736

3.  Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension.

Authors:  Antony Vinh; Wei Chen; Yelena Blinder; Daiana Weiss; W Robert Taylor; Jörg J Goronzy; Cornelia M Weyand; David G Harrison; Tomasz J Guzik
Journal:  Circulation       Date:  2010-11-29       Impact factor: 29.690

4.  Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction.

Authors:  Philip Wenzel; Maike Knorr; Sabine Kossmann; Jan Stratmann; Michael Hausding; Swenja Schuhmacher; Susanne H Karbach; Melanie Schwenk; Nir Yogev; Eberhard Schulz; Matthias Oelze; Stephan Grabbe; Helmut Jonuleit; Christian Becker; Andreas Daiber; Ari Waisman; Thomas Münzel
Journal:  Circulation       Date:  2011-08-29       Impact factor: 29.690

5.  Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension.

Authors:  Paul J Marvar; Salim R Thabet; Tomasz J Guzik; Heinrich E Lob; Louise A McCann; Connie Weyand; Frank J Gordon; David G Harrison
Journal:  Circ Res       Date:  2010-06-17       Impact factor: 17.367

6.  Rostral Ventrolateral Medulla EP3 Receptor Mediates the Sympathoexcitatory and Pressor Effects of Prostaglandin E2 in Conscious Rats.

Authors:  Samar Rezq; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2016-08-29       Impact factor: 4.030

7.  Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension.

Authors:  Heinrich E Lob; David Schultz; Paul J Marvar; Robin L Davisson; David G Harrison
Journal:  Hypertension       Date:  2012-12-17       Impact factor: 10.190

8.  Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility.

Authors:  Lihong Chen; Yifei Miao; Yahua Zhang; Dou Dou; Limei Liu; Xiaoyu Tian; Guangrui Yang; Dan Pu; Xiaoyan Zhang; Jihong Kang; Yuansheng Gao; Shiqiang Wang; Matthew D Breyer; Nanping Wang; Yi Zhu; Yu Huang; Richard M Breyer; Youfei Guan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

9.  Dendritic Cell Amiloride-Sensitive Channels Mediate Sodium-Induced Inflammation and Hypertension.

Authors:  Natalia R Barbaro; Jason D Foss; Dmytro O Kryshtal; Nikita Tsyba; Shivani Kumaresan; Liang Xiao; Raymond L Mernaugh; Hana A Itani; Roxana Loperena; Wei Chen; Sergey Dikalov; Jens M Titze; Bjorn C Knollmann; David G Harrison; Annet Kirabo
Journal:  Cell Rep       Date:  2017-10-24       Impact factor: 9.423

10.  Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction.

Authors:  Tomasz J Guzik; Nyssa E Hoch; Kathryn A Brown; Louise A McCann; Ayaz Rahman; Sergey Dikalov; Jorg Goronzy; Cornelia Weyand; David G Harrison
Journal:  J Exp Med       Date:  2007-09-17       Impact factor: 14.307

View more
  8 in total

Review 1.  Inflammation in Hypertension.

Authors:  Liang Xiao; David G Harrison
Journal:  Can J Cardiol       Date:  2020-01-24       Impact factor: 5.223

Review 2.  Innate immunity and clinical hypertension.

Authors:  Justin P Van Beusecum; Hietor Moreno; David G Harrison
Journal:  J Hum Hypertens       Date:  2021-10-23       Impact factor: 2.877

3.  Central Blockade of E-Prostanoid 3 Receptor Ameliorated Hypertension Partially by Attenuating Oxidative Stress and Inflammation in the Hypothalamic Paraventricular Nucleus of Spontaneously Hypertensive Rats.

Authors:  Fang-Fang Wang; Xiao-Jing Yu; Qiu-Yue Yi; Juan Ba; Xiao-Lian Shi; Jin-Jun Liu; Kai-Li Liu; Li-Yan Fu; Qing Su; Hong-Bao Li; Kai B Kang; Shu-Qiu Wang; Hong-Li Gao; Jie Qi; Ying Li; Guo-Qing Zhu; Yu-Ming Kang
Journal:  Cardiovasc Toxicol       Date:  2020-11-09       Impact factor: 3.231

4.  EP3 (E-Prostanoid 3) Receptor Mediates Impaired Vasodilation in a Mouse Model of Salt-Sensitive Hypertension.

Authors:  Jing Wu; Shi Fang; Ko-Ting Lu; Kelsey Wackman; Michal L Schwartzman; Sergey I Dikalov; Justin L Grobe; Curt D Sigmund
Journal:  Hypertension       Date:  2021-03-01       Impact factor: 9.897

5.  Network and 16S rRNA Sequencing-Combined Approach Provides Insightal Evidence of Vitamin K2 for Salt-Sensitive Hypertension.

Authors:  Tian-Hao Liu; Ming-Hao Chen; Wan-Qing Tu; Qiu-Er Liang; Wen-Cong Tao; Zhen Jin; Ya Xiao; Li-Guo Chen
Journal:  Front Nutr       Date:  2021-02-24

6.  2-Methoxyestradiol Ameliorates Angiotensin II-Induced Hypertension by Inhibiting Cytosolic Phospholipase A2α Activity in Female Mice.

Authors:  Chi Young Song; Purnima Singh; Mustafa Motiwala; Ji Soo Shin; Jessica Lew; Shubha R Dutta; Frank J Gonzalez; Joseph V Bonventre; Kafait U Malik
Journal:  Hypertension       Date:  2021-10-11       Impact factor: 10.190

Review 7.  Pathophysiology of Hypertension: The Mosaic Theory and Beyond.

Authors:  David G Harrison; Thomas M Coffman; Christopher S Wilcox
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

8.  EP3 Receptor Deficiency Improves Vascular Remodeling and Cognitive Impairment in Cerebral Small Vessel Disease.

Authors:  Na Liu; Jie Tang; Yang Xue; Vincent Mok; Miaoyi Zhang; Xue Ren; Yilong Wang; Jianhui Fu
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.